Erratum: Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes (Diabetes (2013) 62 (3224-3231) DOI: 10.2337/db12-1512);Effect of losartan on prevention and progression of early diabetic nephropathy in American indians with type 2 diabetes

Diabetes

Volumn 62, Issue 9, 2013, Pages 3224-3231

  Weil, E Jennifer ^a   Fufaa, Gudeta ^a   Jones, Lois I ^a   Lovato, Tracy ^a   Lemley, Kevin V ^b   Hanson, Robert L ^a   Knowler, William C ^a   Bennett, Peter H ^a   Yee, Berne ^c   Myers, Bryan D ^d   Nelson, Robert G ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c Southwest Kidney Institute   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; HEMOGLOBIN A1C; LOSARTAN;

ADULT; AMERICAN INDIAN; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; FEMALE; GLOMERULAR STRUCTURE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SYSTOLIC BLOOD PRESSURE; URETHRA OBSTRUCTION; AGED; CONTROLLED CLINICAL TRIAL;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INDIANS, NORTH AMERICAN; LOSARTAN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84883309399     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db18-er03a     Document Type: Erratum

References (26)

1. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
2. Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345: 851-860
3. Levey AS, Cattran D, Friedman A, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009;54:205-226
4. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Micro-albuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878
5. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Mul-tifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393
6. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51
7. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2000;23(Suppl. 1):S32-S42
8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153
9. Vasquez B, Flock EV, Savage PJ, et al. Sustained reduction of proteinuria in type 2 (non-insulin-dependent) diabetes following diet-induced reduction of hyperglycaemia. Diabetologia 1984;26:127-133
10. Chasson AL, Grady HJ, Stanley MA. Determination of creatinine by means of automatic chemical analysis. Tech Bull Regist Med Technol 1960;30: 207-212
11. Myers BD, Nelson RG, Tan M, et al. Progression of overt nephropathy in non-insulin-dependent diabetes. Kidney Int 1995;47:1781-1789
12. Weil EJ, Lemley KV, Mason CC, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 2012;82:1010-1017
13. Weibel ER. Practical Methods for Biological Morphometry. New York, Academic Press, 1979
14. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984;74:1143-1155
15. Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 1994;43:1358-1364
16. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997;99:342-348
17. Bilous R, Chaturvedi N, Sjølie AK, et al. Effect of candesartan on micro-albuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009;151:11-20, W3-4
18. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-1792
19. Pavkov ME, Knowler WC, Lemley KV, Mason CC, Myers BD, Nelson RG. Early renal function decline in type 2 diabetes. Clin J Am Soc Nephrol 2012;7:78-84
20. Rudberg S, Osterby R, Bangstad HJ, Dahlquist G, Persson B. Effect of angiotensin converting enzyme inhibitor or beta blocker on glo-merular structural changes in young microalbuminuric patients with type I (insulin-dependent) diabetes mellitus. Diabetologia 1999;42:589-595
21. Ahmad J, Shafique S, Abidi SM, Parwez I. Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. Diabetes Res Clin Pract 2003;60: 131-138
22. White KE, Pinel N, Cordonnier DJ, Bilous RW; Diabiopsies Group. Does ACE inhibition slow progression of glomerulopathy in patients with type 2 diabetes mellitus? Diabet Med 2001;18:933-936
23. Lemley KV, Abdullah I, Myers BD, et al. Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int 2000;58:1228-1237
24. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-1053
25. Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 2006;296:421-426
26. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012;60:850-886